Patrick R. LaFontaine

Sanofi, Cambridge, MA

Applied Genetic Technologies (Ownership Interest includes stock, stock options, patent or other intellectual property)Neos Therapeutics (Ownership Interest includes stock, stock options, patent or other intellectual property)Sanofi (Employment, Ownership Interest includes stock, stock options, patent or other intellectual property)

Poster(s):

• (P-574) Frequency, Characteristics, and Subsequent Treatment (Tx) of Real-world Patients (pts) Who Discontinue Hedgehog Inhibitors (HHIs) as First-line (1L) Systemic Tx for Advanced Basal Cell Carcinoma (aBCC)